- GSK shelves cough drug acquired in $2B deal<figure><div><img src="https://imgproxy.divecdn.com/mDk-h3NLB8udDPFuDlI7IPou1i9tJKJYucQXUnhK9vA/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTc3MzEzMjc4LmpwZ…BioPharma Dive · 7d ago↗ source
- How well are AI-discovered drugs faring in the clinic?<figure><div><img src="https://imgproxy.divecdn.com/FF7gugutgjWeeCEjeDD3aQdzLpVn2Dsf1iRhZmSXUf0/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy02Mzk2MTIwODRfMS5qc…BioPharma Dive · 7d ago↗ source
- GSK drops Phase 3 chronic cough drug in a blow to $2B Bellus Health buyoutIn a major stumble for GSK’s $2 billion acquisition of Bellus Health, the UK pharma said Friday it is ending development of camlipixant in refractory chronic cough (RCC) after the drug ...